8-K: Iris Acquisition Corp. Extends Business Combination Deadline with Liminatus Pharma to July 31, 2024

Iris Acquisition Corp. has extended the deadline to complete its business combination with Liminatus Pharma to July 31, 2024, through a third amendment to their agreement.

Summary

• Iris Acquisition Corp., Iris Parent Holding Corp., and Liminatus Pharma, LLC have agreed to a third amendment to their Business Combination Agreement.
• This amendment extends the deadline for completing the business combination to July 31, 2024.
• The original Business Combination Agreement was dated November 28, 2022, and has been amended twice previously.
• Concurrently, the deadlines for the PIPE Equity Subscription Agreement and the Convertible Note Subscription Agreement were also extended to July 31, 2024.
• All other terms and conditions of the original agreements remain in effect.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the repeated extensions, which suggest potential challenges in completing the merger. While the extension provides more time, it also introduces uncertainty.

Positives

• The extension provides additional time to finalize the business combination.
• The continued commitment from all parties is evident through the amendments.

Negatives

• The need for multiple extensions may indicate challenges in completing the transaction.
• The repeated extensions could cause uncertainty for investors.

Risks

• Failure to complete the business combination by the new deadline could lead to termination of the agreement.
• The repeated extensions may suggest underlying issues that could impact the success of the merger.
• There is a risk that the PIPE financing may not close if the business combination is not completed.

Future Outlook

The company aims to complete the business combination by July 31, 2024, as per the amended agreements.

Management Comments

• The agreements were signed by Sumit Mehta, CEO of Iris Acquisition Corp, and Chris Kim, CEO of Liminatus Pharma and Iris Parent Holding Corp.

Industry Context

The use of a SPAC structure for a business combination is a common practice, particularly in the biotech and pharmaceutical sectors. The extension of deadlines is not uncommon in these types of transactions, often due to the complexities of the deal and market conditions.

Comparison to Industry Standards

• SPAC mergers often face delays, and multiple extensions are not unusual, especially when dealing with complex transactions like those in the pharmaceutical sector.
• Other SPAC deals have also seen similar extensions due to regulatory hurdles, market volatility, or difficulties in completing due diligence.
• The need for multiple extensions could be compared to other SPAC mergers that have struggled to meet initial timelines, such as the merger between Gores Metropoulos and United Wholesale Mortgage, which also faced delays.

Stakeholder Impact

• Shareholders may experience uncertainty due to the repeated extensions.
• Employees of both companies may face uncertainty regarding the future of the merger.
• The delay could impact the timeline for Liminatus Pharma's business plans.

Next Steps

• The parties will work towards completing the business combination by the new deadline of July 31, 2024.
• The PIPE financing is expected to close by the same date.

Key Dates

Keywords

Business Combination, Merger, Acquisition, SPAC, Liminatus Pharma, Iris Acquisition Corp, PIPE Financing, Subscription Agreement, Convertible Note, Deadline Extension